2026-01-27 - Analysis Report
Report: Abbott Laboratories (ABT)

**Company Overview:** Abbott Laboratories is a multinational healthcare company specializing in diagnostic equipment, medical devices, and nutritional products.

**Comparison with S&P 500 (VOO)**

* Cumulative Return:
  - Review Stock (ABT): 55.81%
  - Comparison Stock (VOO): 127.58%
  - Divergence: -71.77% (max: 72.30, min: -72.50, current: -72.50, relative divergence: 0.00%)

**Alpha, Beta Analysis:**

| Period | CAGR | MDD | Alpha | Beta | Cap(B) |
|------|------|------|-------|------|-------|
| 2016-2018 | 54.0% | 11.7% | 45.0% | 1.1 | 125.9B |
| 2017-2019 | 64.0% | 11.7% | 39.0% | 1.0 | 151.2B |
| 2018-2020 | 51.0% | 29.7% | 27.0% | 0.9 | 190.6B |
| 2019-2021 | 76.0% | 29.7% | 12.0% | 0.8 | 244.9B |
| 2020-2022 | 0.0% | 28.9% | -4.0% | 0.8 | 191.1B |
| 2021-2023 | -56.0% | 26.1% | -74.0% | 0.7 | 191.6B |
| 2022-2024 | -43.0% | 21.3% | -72.0% | 0.7 | 196.9B |
| 2023-2025 | 7.0% | 19.0% | -69.0% | 0.3 | 218.1B |

**Recent Stock Price Fluctuations:**

* Close: $108.77
* Last-Market: $108.77 (up $1.35)
* Moving Averages: 
  - 5-day SMA: $113.33
  - 20-day SMA: $122.20
  - 60-day SMA: $124.78

**RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence:**

* Market Risk Indicator (MRI): 0.70
* RSI: 13.83 (oversold)
* PPO: -1.59 (sell)
* Hybrid Signal: Buy (Cash 0%)
* Risk Level: Medium
* Recent (20 days) relative divergence change: -0.50 (-): worsening
* 7-day Rank change: 8 (+): rank up
* 7-day Dynamic Expected Return change: 721.10 (+): improving
* Expected Return (%): -884.20% (large decline)

**Recent News & Significant Events:**

Based on the provided news, it seems that Abbott Laboratories is facing some challenges, including a sharp decline in stock price and disappointing quarterly results. However, there are also positive developments, such as insider purchases and a deal with Exact Sciences to target cancer diagnostics. It is essential to monitor the situation closely and consider various factors before making any investment decisions.

**Analyst Opinions:**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.76 (~Buy)
- Opinions: 25
- Target Price (avg/high/low): $136.47 / $169.00 / $115.00

**Recent Earnings Analysis:**

| Date | EPS | Revenue |
|---|---:|---:|
| 2025-10-29 | 0.94 | $11.37 B |
| 2025-07-30 | 1.02 | $11.14 B |
| 2025-04-30 | 0.76 | $10.36 B |
| 2024-10-31 | 0.94 | $10.63 B |
| 2025-10-29 | 0.94 | $10.63 B |

The recent earnings analysis suggests that Abbott Laboratories has been experiencing fluctuations in revenue and EPS. However, the EPS seems to be recovering from the previous quarter. It is crucial to monitor the company's financial performance closely.

**Financial Information:**

Revenue and Profitability:

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $11.37B | 55.36% |
| 2025-06-30 | $11.14B | 56.44% |
| 2025-03-31 | $10.36B | 56.86% |
| 2024-12-31 | $10.97B | 54.97% |

Capital and Profitability:

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $50.95B | 3.23% |
| 2025-06-30 | $50.56B | 3.52% |
| 2025-03-31 | $48.81B | 2.71% |
| 2024-12-31 | $47.66B | 19.36% |

The financial information suggests that Abbott Laboratories has been experiencing fluctuations in revenue and profitability. However, the company's equity has been increasing over time, which could be a positive indicator. It is essential to monitor the company's financial performance closely and consider various factors before making any investment decisions.

**Comprehensive Analysis:**

* Cumulative Return: -71.77% (divergent from S&P 500)
* Recent Stock Price Fluctuations: sharp decline in stock price
* RSI, PPO Index Indicators: oversold and sell signals
* Analyst Opinions: buy consensus
* Recent Earnings Analysis: fluctuating revenue and EPS
* Financial Information: fluctuations in revenue and profitability

Based on the comprehensive analysis, it appears that Abbott Laboratories is facing some challenges, including a sharp decline in stock price and disappointing quarterly results. However, there are also positive developments, such as insider purchases and a deal with Exact Sciences to target cancer diagnostics. It is essential to monitor the situation closely and consider various factors before making any investment decisions.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.